Introduction to Inflammatory Bowel Diseases Flashcards

1
Q

IBD

A

o IBD is chronic or recurring inflammation of the GI tract due to dysregulated immune response
o IBD IS NOT THE SAME AS IBS!!

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

prevalence of IBD

A
  • Approximately 1.85M patients with IBD in US

- Slightly more UC > CD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

incidence of IBD

A
  • Slight M > F in UC
  • Slight F > M in CD
  • Majority diagnosed young (15-35yo)
  • Bimodal distribution with small bump in new diagnoses 60-70s yo (M>F in late UC dx, F>M in late CD dx)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Ulcerative colitis

A
  • Term first used in 1875 by Samuel Wilks and Walter Moxon to differentiate case of inflamed colon from infectious diarrhea
  • Involves ONLY the colon
  • Always involves the rectum, can involve the colon more proximally in a continuous fashion
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

UC pathology

A

-Limited to mucosa and submucosa

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

UC clinical manifestations

A
  • Bloody diarrhea (Mucus, Frequency, Urgency, Tenesmus, Nocturnal bowel movements)
  • Abdominal pain
  • Constitutional symptoms (Fatigue, Anorexia, Weight loss)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Chron’s disease

A
  • Named after Dr. Burrill B. Crohn who published a landmark paper in 1932 describing the features of what is known today as Crohn’s disease
  • Can affect ANY portion of the digestive tract from mouth to anus (Small bowel disease only: 30%, Ileocolonic disease: 40%, Colonic disease only: 30%, Upper GI tract: 0.5-4%, Perianal disease: 33% (5% anus only))
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

chrons pathology

A
  • Involves entire thickness (“transmural inflammation”)

- Will involve cobblestoning

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

consequences of transmural inflammation

A
  • Abscess
  • Fistula – connecting from one space to another
  • Stricture
  • The inflammation breaks down the wall and the fecal matter goes to a different lumen
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Clinical symptoms of CD

A
  • Highly variable depending on location of inflammatory process
  • Colonic: can be similar to ulcerative colitis (Diarrhea, Blood in stool, Abdominal pain, Weight loss, weakness and anorexia)
  • Small bowel (Diarrhea, usually non-bloody, Abdominal pain, Fever/weight loss/anorexia, Malabsorption/malnutrition, Stricturing – nausea, vomiting, bloating, food aversion, Perforating - FUO, Sepsis)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

risk factors for inflammatory bowel disease

A
  • Heritability (One parent with UC = 2% chance of offspring with IBD, One parent with Crohn’s disease = 5%, Both parents with IBD = 36%, Monozygotic twin studies show 18% and 58% concordance in UC and CD, respectively)
  • Race/Ethnicity (Ashkenazi Jewish and Caucasians vs Navajo Indians)
  • Industrialization, urban areas, northern climates (Leading markets US (prevalence: 319/100,000) and Europe (322/100,000) vs China 1-2/100,000)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

geographic distribution of inflammatory bowel disease

A
  • Rates highest in northern locales
  • More common in Caucasians than in blacks
  • Less common in Asians and Hispanics
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

risk factors for inflammatory bowel disease

A
  • Smoking (Increases risk of CD, Is PROTECTIVE in UC)
  • NSAIDs
  • ? Other medications (Accutane, OCPs)
  • ? Appendicitis – children who had appendectomy may have reduced risk of UC but higher increased risk of CD
  • ? Diet (high in animal protein)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

fecal microbiota are abnormal in IBD

A
  • UC and CD fecal microbiota are distinct from each other as well as from infectious colitis and normal patients
  • Depleted microbiome diversity has been demonstrated in both CD and UC
  • Colonic microbiome contribute to multiple functions critical to health (Metabolism of insoluble carbohydrates, Vitamin / micronutrient production, Immune development and homeostasis, Ancillary mucosa protection)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

challenges to treating IBD

A
  • Often fluctuating disease severity and disease “flares”
  • Treatments don’t work for everyone
  • Treatments that do initially work may stop working
  • Drugs are expensive
  • Drugs have side effects and safety concerns
  • Patients may want to stop treatment
  • No one-size-fits-all
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

goals of therapy

A
  • Improve clinical symptoms (Induce and maintain clinical remission)
  • Decrease hospitalization/surgery
  • Minimize disease and treatment-related complications
  • Heal mucosal lesions
17
Q

factors influencing treatment

A
  • Ulcerative colitis or Crohn’s disease
  • Disease severity
  • Anatomic location of disease
  • Previous response to medications
  • Side effects of medications
  • Comorbidities
  • Patient preferences
18
Q

pharmacologic treatments

A
  • 5-Aminosalicylates (5-ASA)
  • Immunomodulators (AZA, 6-MP, MTX)
  • Biologics (Anti-TNF, Alpha-4, beta-7 integrin receptor antagonists)
  • Corticosteroids
  • Antibiotics
19
Q

5-aminosalicylates (5-ASA)

A
  • Major drug in class is mesalamine
  • Anti-inflammatory compounds
  • Decrease inflammation in wall of intestine
  • Can be given orally or rectally
  • Generally very safe
  • Primarily used for treatment of mild UC for induction and maintenance of remission
  • Efficacy in Crohn’s disease is marginal (Mesalamine does not have an FDA indication for CD, Monotherapy can be considered for mild Crohn’s limited to the colon)
20
Q

immunomodulators

A
  • Modifies activity of immune system to reduce ongoing inflammation
  • Members: 6-mercaptopurine (6-MP), Azathioprine (AZA, prodrug of 6-MP), Methotrexate (MTX)
  • Used in treatment of IBD for 40+ years
  • Slow onset of action (~ 6 months)
21
Q

adverse effects of immunomodulators

A
  • Infectious complications (7%): serious 2%
  • Myelosuppression 5%
  • Transaminase elevation 10% (dose-dependent)
  • Lymphoma (1/2000)
  • Increase in non-melanoma skin cancers
  • Nausea/dyspepsia up to 20%
  • Up to 20% discontinue due to AEs
22
Q

how anti-TNFs work

A

-A lot of the strategies are finding the molecule first and then finding something that will bind it

23
Q

Limitation of biologics

A
  • 40% of primary responders lose response to the drug over time
  • Loss of response (LOR) can be caused by accelerated clearance of the drug especially upon formation of antibodies against the drug
  • Extremely expensive (>$15,000/year)
  • Requires either self-injection or infusion
24
Q

TNF safety issues

A
  • Tuberculosis reactivation
  • Hepatitis B reactivation
  • Reactivation of opportunistic infections
  • Malignancy / lymphoma
  • Neurologic events/ demyelination syndromes
  • Cardiovascular events
  • Deaths
25
Q

corticosteroids

A
  • Prednisone continues to be the mainstay of treatment for patients with acute flares of IBD
  • Multiple adverse effects associated with steroid use prevents use in maintenance
  • Patients who are steroid-dependent should be started on biologics early on to prevent morbidity of chronic steroid exposure
26
Q

short-term adverse effects of prednisone

A
  • Weight gain
  • Fluid retention
  • Sleep disturbance
  • Mood swings
  • Acne
27
Q

long-term adverse effects of prednisone

A
  • Infection
  • Bone loss / osteoporosis
  • Cataracts / Glaucoma
  • Skin fragility
  • Hypertension
  • Diabetes
28
Q

budesonide

A
  • Glucocorticoid with high affinity for GI tract but low systemic activity due to extensive first-pass metabolism in the liver
  • ”Prednisone lite”
  • Less effective than prednisone but substantially fewer corticosteriod adverse events
29
Q

other treatment options

A
  • Diet – Mediterranean diet, low FODMAPs diet
  • Supplements – Tumeric!
  • Marijuana?
  • Fecal transplant?
  • Helminth therapy?
  • Surgery